-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Creative Planning Has $594,000 Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)
Creative Planning Has $594,000 Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)
Creative Planning raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 21.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,424 shares of the medical research company's stock after buying an additional 247 shares during the quarter. Creative Planning's holdings in Bio-Rad Laboratories were worth $594,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in the business. Veritas Asset Management LLP bought a new stake in shares of Bio-Rad Laboratories during the second quarter valued at approximately $379,547,000. Millennium Management LLC grew its holdings in Bio-Rad Laboratories by 19.3% during the second quarter. Millennium Management LLC now owns 379,329 shares of the medical research company's stock worth $187,768,000 after buying an additional 61,424 shares in the last quarter. Prudential Financial Inc. grew its holdings in Bio-Rad Laboratories by 181.0% during the first quarter. Prudential Financial Inc. now owns 85,053 shares of the medical research company's stock worth $47,905,000 after buying an additional 54,789 shares in the last quarter. Brown Advisory Inc. grew its holdings in Bio-Rad Laboratories by 8.2% during the second quarter. Brown Advisory Inc. now owns 629,845 shares of the medical research company's stock worth $314,245,000 after buying an additional 47,921 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in Bio-Rad Laboratories by 11.3% during the first quarter. Invesco Ltd. now owns 352,100 shares of the medical research company's stock worth $198,311,000 after buying an additional 35,635 shares in the last quarter. 64.35% of the stock is owned by institutional investors and hedge funds.
Get Bio-Rad Laboratories alerts:Bio-Rad Laboratories Trading Up 1.3 %
Shares of BIO opened at $473.42 on Thursday. Bio-Rad Laboratories, Inc. has a fifty-two week low of $344.63 and a fifty-two week high of $670.61. The business has a 50-day moving average of $429.97 and a 200 day moving average of $447.17. The firm has a market cap of $14.12 billion, a P/E ratio of -2.35 and a beta of 0.91. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.30 and a current ratio of 5.50.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on BIO shares. TheStreet downgraded Bio-Rad Laboratories from a "c" rating to a "d+" rating in a report on Thursday, October 27th. StockNews.com downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, January 18th. Royal Bank of Canada started coverage on Bio-Rad Laboratories in a research note on Tuesday, December 6th. They issued an "outperform" rating and a $565.00 price objective for the company. Finally, Credit Suisse Group reduced their price objective on Bio-Rad Laboratories from $715.00 to $640.00 and set an "outperform" rating for the company in a research note on Friday, October 28th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $651.25.Bio-Rad Laboratories Company Profile
(Get Rating)
Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.
See Also
- Get a free copy of the StockNews.com research report on Bio-Rad Laboratories (BIO)
- Bed Bath & Beyond Is Circling the Drain
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
根据创意策划公司最近向美国证券交易委员会披露的信息,该公司在第三季度将其在Bio-Rad实验室公司(纽约证券交易所代码:BIO-GET评级)的持股增加了21.0%。该公司在本季度额外购买了247股后,持有这家医学研究公司1,424股股票。截至最近提交给美国证券交易委员会的文件,创意策划持有的Bio-Rad实验室股份价值59.4万美元。
其他几家机构投资者最近也增持或减持了该公司的股份。Veritas Asset Management LLP在第二季度购买了Bio-Rad实验室的新股份,价值约379,547,000美元。千禧管理有限责任公司在第二季度增持了19.3%的Bio-Rad实验室股份。Millennium Management LLC现在持有这家医学研究公司379,329股股票,价值187,768,000美元,上个季度又购买了61,424股。保诚金融第一季度增持了181.0%的Bio-Rad实验室股份。保诚金融公司现在持有85,053股这家医疗研究公司的股票,价值47,905,000美元,在上个季度又购买了54,789股。第二季度,Brown Consulting Inc.对Bio-Rad实验室的持股增加了8.2%。Brown Consulting Inc.现在持有这家医学研究公司629,845股股票,价值314,245,000美元,上个季度又购买了47,921股。最后,景顺在第一季度增持了Bio-Rad实验室11.3%的股份。景顺公司目前持有352,100股这家医疗研究公司的股票,价值198,311,000美元,上个季度又购买了35,635股。64.35%的股票由机构投资者和对冲基金持有。
到达Bio-Rad实验室警报:Bio-Rad实验室股价上涨1.3%
周四,BIO的股价开盘报473.42美元。Bio-Rad实验室公司的股价为344.63美元,为52周低点,52周高点为670.61美元。该业务的50日移动均线切入位在429.97美元,200日移动均线切入位在447.17美元。该公司的市值为141.2亿美元,市盈率为-2.35,贝塔系数为0.91。该公司的负债权益比率为0.14,速动比率为4.30,流动比率为5.50。
分析师升级和下调评级
几位股票研究分析师最近发布了关于BIO股票的报告。华尔街在10月27日星期四的一份报告中将Bio-Rad实验室的评级从“c”下调至“d+”。在1月18日星期三的一份研究报告中,StockNews.com将Bio-Rad实验室的评级从“买入”下调至“持有”。加拿大皇家银行在12月6日星期二的一份研究报告中开始了对Bio-Rad实验室的报道。他们给出了“跑赢大盘”的评级,并为该公司设定了565.00美元的目标价。最后,瑞士信贷集团将Bio-Rad实验室的目标价从715.00美元下调至640.00美元,并在10月28日星期五的一份研究报告中为该公司设定了“跑赢大盘”的评级。一位股票研究分析师将该股的评级定为持有,四位分析师将该公司的评级定为买入。根据MarketBeat,该股目前的共识评级为“适度买入”,平均目标价为651.25美元.Bio-Rad实验室公司简介
(获取评级)
Bio-Rad实验室公司致力于开发和生产用于生化、制药和其他生命科学研究应用的特殊化学品。它通过生命科学和临床诊断部门开展业务。生命科学部门开发、制造和销售试剂、仪器和实验室仪器。
另请参阅
- 免费获取StockNews.com关于Bio-Rad实验室的研究报告(BIO)
- Bed Bath&Beyond正在绕着排水沟走
- Allegro MicroSystems是一只定位良好的半导体股票
- 斯科特奇迹-Gro触底,比赛逆转
- 奥驰亚是一只大衰退的股票,长期前景不确定
- Novavax的股价在1月份大幅上涨,而其他股票则出现下滑
每天收到Bio-Rad实验室的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Bio-Rad实验室和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧